The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial.
Gael Deplanque
No relevant relationships to disclose
Martin Demarchi
No relevant relationships to disclose
Mohamed Hebbar
No relevant relationships to disclose
Patrick J. Flynn
No relevant relationships to disclose
Bohuslav Melichar
No relevant relationships to disclose
James Atkins
No relevant relationships to disclose
Philippe Ruszniewski
No relevant relationships to disclose
Eric Raymond
Consultant or Advisory Role - Lilly
Research Funding - Lilly
Olivier Hermine
Employment or Leadership Position - AB Science
Stock Ownership - AB Science
Pascal Hammel
Consultant or Advisory Role - Novartis
Honoraria - Merck Serono; Pfizer